Medicare Will Cover Wegovy and Zepbound for Weight Loss: The GLP-1 Bridge Program Explained

For years, many Medicare beneficiaries who wanted weight management medications like Wegovy or Zepbound were locked out by Medicare’s coverage rules. That is about to change.

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a short-term program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay per month. The Bridge runs through December 31, 2027.

You may have also heard about a larger program called the BALANCE Model. That model is still moving forward for Medicaid, but the Medicare Part D piece has been delayed indefinitely. For now, the GLP-1 Bridge is the active program that Medicare beneficiaries will actually use.

This guide explains how the GLP-1 Bridge works, which drugs are covered, who qualifies, what it costs, and what you can do right now.

First, a Quick Note on Medicare Part D

Part D is the part of Medicare that covers prescription drugs. You typically get it either as a standalone drug plan or as part of a Medicare Advantage plan that includes drug coverage. The GLP-1 Bridge uses Part D in one specific way: you must be enrolled in a Part D plan to qualify. Think of it as your entry ticket.

Here is the part that trips people up. Even though you need a Part D plan to be eligible, the Bridge does not run through your Part D plan. CMS pays for and processes these drugs separately, on its own. Your plan does not cover the cost and is not involved in the transaction.

This matters later in two places. It is why the drug list is limited to a few products, and it is why the $50 you pay does not behave like a normal Part D copay (more on that in the cost section).

A separate, larger program called the BALANCE Model would have built GLP-1 weight loss coverage directly into Part D plans, so your own plan would cover it. That is the piece that has been delayed indefinitely. So Part D is still central to the Bridge as an eligibility requirement, even though the plan-based BALANCE coverage is not happening for now.

Why Haven’t Weight Loss Drugs Been Covered by Medicare?

When Congress created Medicare Part D in 2003, the law specifically excluded coverage for drugs used for weight loss. At the time, weight loss medications were not as effective as they are today, and obesity was not yet widely treated as a chronic medical condition.

This meant that even if a Part D plan wanted to cover a weight loss drug, it could not legally do so.

That is why a drug like Ozempic has only been covered by Part D when prescribed for type 2 diabetes, not for weight management. Today, Part D plans can also cover certain GLP-1s for other approved medical uses, such as reducing cardiovascular risk and treating obstructive sleep apnea. Coverage for weight loss alone, however, has remained off the table.

What Has Changed?

Medicine has come a long way since 2003. GLP-1 medications have been shown in clinical trials to help people lose significant amounts of weight, results that used to be associated mainly with bariatric surgery.

Research now recognizes that obesity can contribute to type 2 diabetes, cardiovascular disease, and other serious conditions. According to the CDC, about 40% of U.S. adults have obesity, and many more are overweight. GLP-1 drugs have become widely used, but they have also been expensive and hard to afford, which is part of what these new programs aim to address.

What Is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term demonstration run directly by CMS. It provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs for weight loss between July 1, 2026 and December 31, 2027.

Here is what makes the Bridge different from regular Part D coverage:

• It runs outside the normal Part D system. Part D plans do not carry the financial cost and do not have to opt in for you to get access. CMS uses a single central processor to handle prior authorization, claims, and payment to pharmacies.
• It is nationwide. The Bridge is available in all states and territories.
• It is temporary. The program is currently scheduled to end December 31, 2027.

The Bridge was created as a stepping stone to the larger BALANCE Model. Because the Part D portion of BALANCE has been delayed (more on that below), the Bridge was extended through the end of 2027 and is now the main pathway for Medicare beneficiaries seeking GLP-1 coverage for weight loss.

What Medications May Be Covered?

The Bridge covers a specific, limited list of GLP-1 medications when prescribed for weight loss. According to CMS, the covered products are:

• Wegovy (semaglutide), all formulations, including the injection and the tablet
• Zepbound KwikPen (tirzepatide), the once-weekly injector pen only
• Foundayo (orforglipron), a once-daily pill, all formulations

Important: Not every GLP-1 is covered under the Bridge. Ozempic, Mounjaro, Rybelsus, and Saxenda are not on the Bridge list for weight loss. For Zepbound, only the KwikPen version is included; the single-dose vials and single-dose pens are not. This list may be updated over the course of the program.

These drugs work by mimicking natural hormones in your digestive system. They reduce appetite, slow digestion, and help you feel full longer, which can lead to weight loss when combined with diet and exercise.

Timeline: When Could You Get Access?

July 1, 2026: Medicare GLP-1 Bridge launches

Starting July 1, 2026, eligible Medicare Part D beneficiaries can begin accessing covered GLP-1 medications for $50 a month. This is the program that is actually starting now.

December 31, 2027: Bridge currently scheduled to end

The Bridge was extended from its original December 2026 end date to run through the end of 2027. CMS is using the extra time to collect data on GLP-1 use that could inform a future Part D program.

BALANCE Model for Medicare Part D: delayed indefinitely

The full BALANCE Model was originally scheduled to begin for Medicare Part D in January 2027. In April 2026, CMS announced it would not move forward with the Part D portion of BALANCE in 2027, citing the need for more data and a smoother transition. Reporting indicated that there was not enough interest among Part D plans to launch the model as designed. There is no confirmed date for BALANCE to begin in Medicare Part D, which means coverage after 2027 is uncertain.

May 2026: BALANCE Model for Medicaid

The Medicaid portion of BALANCE is moving ahead. States that choose to participate can begin as early as May 2026, with coverage rolling out on a state-by-state basis. According to KFF, only about 13 states covered GLP-1s for weight loss under Medicaid as of January 2026.

Who Is Eligible for the GLP-1 Bridge?

To qualify for the Medicare GLP-1 Bridge, you must be enrolled in a Medicare Part D plan and meet the clinical criteria below. According to CMS, eligible plan types include a standalone prescription drug plan (PDP) or a Medicare Advantage plan that includes drug coverage (MA-PD). Some plan types, such as private fee-for-service plans and PACE, are not eligible unless you also have a standalone PDP.

Your provider must confirm that you are using the medication to reduce excess body weight and keep it off, along with ongoing lifestyle changes (structured nutrition and physical activity) consistent with the drug’s FDA-approved label. In addition, you must meet one of the three clinical criteria set by CMS, measured at the time you start GLP-1 therapy:

• BMI of 35 or higher (and age 18 or older), or
• BMI of 30 or higher (and age 18 or older), plus one of the following: heart failure with preserved ejection fraction, uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite treatment with two blood pressure medications), or chronic kidney disease stage 3a or above, or
• BMI of 27 or higher (and age 18 or older), plus one of the following: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease

If you take a GLP-1 for another condition, the Bridge is not for you. People who are prescribed a GLP-1 for type 2 diabetes, obstructive sleep apnea, or MASH (a liver condition) can already get coverage through their Part D plan and should continue using that route. The Bridge only covers GLP-1s prescribed for weight management.

Already lost weight on a GLP-1? You can still qualify. The program covers using these drugs to maintain weight loss, and your provider can attest that you met the BMI criteria at the time you first started therapy, even if that was before July 2026.participation, and whether you meet the eligibility requirements.

What Will It Cost?

If you are eligible, you will pay a $50 copay for each 30-day supply of a covered GLP-1 medication under the Bridge. That copay stays the same no matter which phase of your Part D benefit you are in. For comparison, the list prices for these drugs have historically run more than $1,000 a month.

Because the Bridge runs outside the normal Part D benefit, there are a few important details to understand:

• Your Part D deductible does not apply to these drugs.
• The $50 copay does not count toward your Part D out-of-pocket maximum (set at $2,100 in 2026 and $2,400 in 2027).
• If you receive the Low-Income Subsidy (Extra Help), that subsidy does not reduce the $50 copay under the Bridge. The copay stays $50 for everyone who qualifies.

Behind the scenes, participating manufacturers have agreed to a net price of $245 per month for these drugs under the Bridge. That is what CMS and manufacturers settled on, not what you pay. Your cost at the pharmacy is the $50 copay.

Lifestyle Changes Are Part of the Program

The Bridge is built around the idea that weight management medications work best alongside healthy habits. To qualify, your prescription must come with ongoing lifestyle changes, including structured nutrition and physical activity, consistent with the medication’s FDA-approved label.

The larger BALANCE Model is also designed to pair medication with a manufacturer-provided lifestyle support program at no extra cost, covering things like healthy eating guidance, physical activity, and support for building lasting habits. Full details of those programs have not yet been released by CMS.

What Can You Do Right Now?

The Bridge launches July 1, 2026. Here is how to prepare:

• Stay informed. CMS is releasing more details, including the prior authorization process, on its Medicare GLP-1 Bridge page ahead of the launch.

• Talk to your doctor. If you are interested in weight management medication, your provider can help determine whether a covered GLP-1 is right for you and whether you meet the clinical criteria.

• Know that you do not need to register or opt in. CMS has said beneficiaries do not need to take any action to sign up. Access happens through your provider and pharmacy.

• Understand the prior authorization step. To get a covered drug, your provider submits a prior authorization request and prescription to the CMS central processor. These requests cannot be processed before July 1, 2026, so expect some patience may be needed at launch.

• Make sure you have Part D coverage. You must be enrolled in an eligible Part D plan to use the Bridge. During the Annual Enrollment Period (October 15 through December 7), you can review and change your drug coverage.

• Check your current coverage first. If you take a GLP-1 for type 2 diabetes, cardiovascular risk, or sleep apnea, you may already have coverage through your Part D plan, and that is the correct route for those conditions.

Have Questions About Medicare?

If you would like help understanding your Medicare options or want to learn more as details come out about the GLP-1 Bridge and the BALANCE Model, our licensed insurance agents are happy to help.

PlanFit is a licensed insurance agency. We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.